RAS proteins are binary switches, cycling between ON and OFF states during signal
transduction. These switches are normally tightly controlled, but in RAS-related diseases …

Uncontrolled cellular proliferation, mediated by dysregulation of the cell-cycle machinery
and activation of cyclin-dependent kinases (CDKs) to promote cell-cycle progression, lies at …

Sarcomas are malignant soft tissue and bone tumours affecting adults, adolescents and
children. They represent a morphologically heterogeneous class of tumours and some …

Soft-tissue sarcomas represent a heterogeneous group of cancer, with more than 50
histological subtypes,. The clinical presentation of patients with different subtypes is often …

There are more than 70 distinct sarcomas, and this diversity complicates the development of
precision-based therapeutics for these cancers. Prospective comprehensive genomic …

The genetic, biologic, and clinical heterogeneity of sarcomas poses a challenge for the
identification of therapeutic targets, clinical research, and advancing patient care. Because …

Sarcomas are a broad family of mesenchymal malignancies exhibiting remarkable histologic
diversity. We describe the multi-platform molecular landscape of 206 adult soft tissue …

Despite more than three decades of intensive effort, no effective pharmacological inhibitors
of the RAS oncoproteins have reached the clinic, prompting the widely held perception that …

Abstract Cyclin-dependent kinase (CDK) 4/6 inhibition in combination with endocrine
therapy is the standard-of-care treatment for patients with advanced-stage hormone receptor …

Response to immune checkpoint blockade in mesenchymal tumors is poorly characterized,
but immunogenomic dissection of these cancers could inform immunotherapy mediators. We …